Efficacy and safety of CD19 ‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET , ZUMA ‐1, and TRANSCEND trials-Reference-Cited by-同舟云学术

Efficacy and safety of CD19 ‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET , ZUMA ‐1, and TRANSCEND trials

Published:2021-08-13 Issue:10 Volume:96 Page:1295-1312
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Westin Jason R.¹^ORCID,Kersten Marie José²,Salles Gilles³,Abramson Jeremy S.⁴,Schuster Stephen J.⁵,Locke Frederick L.⁶,Andreadis Charalambos⁷

Affiliation:

1. Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston Texas USA

2. Department of Hematology Amsterdam UMC, University of Amsterdam, LYMMCARE (Lymphoma and Myeloma Center Amsterdam) Amsterdam The Netherlands

3. Memorial Sloan Kettering Cancer Center New York New York USA

4. Center for Lymphoma Massachusetts General Hospital Cancer Center Boston Massachusetts USA

5. Lymphoma Program Abramson Cancer Center, University of Pennsylvania Philadelphia Pennsylvania USA

6. Department of Blood and Marrow Transplant and Cellular Immunotherapy Moffitt Cancer Center Tampa Florida USA

7. Helen Diller Family Comprehensive Cancer Center University of California San Francisco San Francisco California USA

Funder

Novartis

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26301

Reference74 articles.

1. Chimeric Antigen Receptor Therapy

2. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

3. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

4. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

5. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin’s Lymphoma;Clinical Pharmacokinetics;2024-09-06

2. Reprogramming natural killer cells for cancer therapy;Molecular Therapy;2024-09

3. Re-examining the role of hematopoietic stem cell transplantation in relapsed large B-cell lymphoma in the era of chimeric antigen receptor (CAR) T-cell therapy;Frontiers in Oncology;2024-08-15

4. New and developing first line pharmacotherapies for treating non-Hodgkin lymphoma;Expert Opinion on Pharmacotherapy;2024-08-12

5. TALEN-edited allogeneic inducible dual CAR T cells enable effective targeting of solid tumors while mitigating off-tumor toxicity;Molecular Therapy;2024-08